 microcombinatorial hydrogel particles, CGPs, have been developed to target metastatic foci in the lungs of patients with breast cancer. These particles consist of a deformable and biodegradable polymeric skeleton which can be loaded with multiple therapeutic and imaging agents such as dostaxel nanoparticles. When injected into the lungs, these particles accumulate at the metastatic foci and release their payload over time, resulting in improved survival rates for patients. This technology has potential applications in treating other types of metastatic diseases as well. This article was authored by Anna-Lisa Palange, Daniela DeMoscolo, Miguel Ferreira, and others.